UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	Washington, D.C. 20549
	FORM 8-K
	CURRENT REPORT
Pursuant to	Section 13 or 15(d) of the Securities Exchange Act of 193
Date of	Report (Date of earliest event reported) May 18, 2011
(E	BIOSCRIP, INC. xact name of Registrant as specified in its charter)

Delaware 0-28740 05-0489664

	(State of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)		
	100 Clearbrook Road, Elmsford, N (Address of principal executive		10523 (Zip Code)		
	Registrant's to	elephone number, including area co	ode: (914) 460-1600		
N/A		ame or former address, if changed s	since last report)		
	eck the appropriate box below if the registrant under any of the followin	_	ultaneously satisfy the filing obligation of		
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				

Item 1.01 Entry into a Material Definitive Agreement.

On May 18, 2011, BioScrip, Inc. (referred to herein as "the Company") entered into the First Amendment and Waiver (the "Amendment") to its Amended and Restated Credit Agreement (the "Amended and Restated Credit Agreement") dated as of December 28, 2010, by and among the Company, as borrower, all of its subsidiaries as subsidiary guarantors thereto, the lenders party thereto, Healthcare Finance Group, LLC, as administrative agent for the lenders, as collateral agent and as collateral manager for the secured parties, and the other entities party thereto.

The Amendment amends certain of the reporting requirements of the Company set forth in the Amended and Restated Credit Agreement and waives any prior non-compliance relating to such reporting requirements.

The foregoing description of the Amendment is qualified in its entirety by the Amendment filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No. Description

First Amendment and Waiver to the Amended and Restated Credit Agreement, dated as of May 18, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSCRIP, INC.

Date: May 23, 2011 /s/ Barry A. Posner
By: Barry A. Posner

Executive Vice President, Secretary and

General Counsel

EXHIBIT INDEX

Exhibit No. Description

10.1 First Amendment to the Amended and Restated Credit Agreement, dated as of May 18, 2011